Obesity: An insight into its neurochemical basis and treatment

Indian Journal of Pharmacology

Volumn 31, Issue 6, 1999, Pages 388-403

  Kulkarni, S K ^a   Kaur, Gurpreet ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Energy expenditure; Energy intake; Neuropeptides; Neurotransmitters; Obesity; Treatment strategies

Indexed keywords

4 (3 TERT BUTYLAMINO 2 HYDROXYPROPOXY) 2 BENZIMIDAZOLONE; 4 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL]PHENOXYACETIC ACID; 5 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL] 1,3 BENZODIOXOLE 2,2 DICARBOXYLIC ACID; ALPHA INTERMEDIN; ALPRENOLOL; ANTIOBESITY AGENT; BETA 3 ADRENERGIC RECEPTOR; BUCINDOLOL; CARAZOLOL; CHOLECYSTOKININ; CORTICOTROPIN RELEASING FACTOR; DEXFENFLURAMINE; FENFLURAMINE; FLUOXETINE; GALANIN; GLUCAGON LIKE PEPTIDE 1; LEPTIN; LIPOPROTEIN LIPASE; MELANIN CONCENTRATING HORMONE; MELANOCORTIN RECEPTOR; NEUROPEPTIDE; NEUROPEPTIDE Y; NEUROTENSIN; NEUROTRANSMITTER; OXPRENOLOL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; SEROTONIN; TUMOR NECROSIS FACTOR ALPHA; UNCOUPLING PROTEIN; UNINDEXED DRUG;

BODY MASS; BODY WEIGHT; BROWN ADIPOSE TISSUE; CALORIC INTAKE; CARDIOVASCULAR RISK; DRUG METABOLISM; ENERGY BALANCE; ENERGY EXPENDITURE; GENETIC PREDISPOSITION; HUMAN; HYPOTHALAMUS VENTROMEDIAL NUCLEUS; NEUROCHEMISTRY; NONHUMAN; NUTRITION; OBESITY; PHYSICAL ACTIVITY; PREVALENCE; PSYCHOLOGICAL ASPECT; REVIEW; THERMOGENESIS;

EID: 0033376972     PISSN: 02537613     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (88)

1. Dvorak R, Starling RD, Calles-Escandon J, Sims EA, Poehlman ET. Drug therapy for obesity in elderly. Drugs Ageing 1997;11:338-51.
2. Consultation on obesity. Geneva, Switzerland: World Health Organisation ; June 3-5, 1997.
3. Caterson ID. Obesity and its management. Australian Prescriber 1999;22:12-16.
4. Mason R Obesity - new insights into a growing problem. Pharmaceu J 1997;258:800-2.
5. Bjorntop P. Obesity. Lancet 1997;350:423-6.
6. Rippe JM, Crossley S, Ringer R. Obesity as a chronic disease: Modern medical and lifestyle management. J Am Diet Assoc 1998;98:9-15
7. York YA. Lessons from animal models of obesity. Endocrin Metab Clin North Am 1996;25:781-97.
8. Bray GA. Genetic, hypothalamic and endocrine features of clinical and experimental obesity. In: Progress in Brain Research, Swaab, D.F., Hofman, M.A., Mirmiran, M. (Editors), Amsterdam, The Netherlands: Elsevier Science Publishers 1992;93:333-41.
9. Wilson CA, Cavalla D. Update on antiobesity drugs. Drugs News Perspect 1998;11:240-7.
10. Poppitt SD. Energy density of diets and obesity. Int J Obes 1995;5:20-6.
11. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Freidman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994;372:425-32.
12. Bray GA, York DA. Hypothalamic and genetic obesity in experimental animals : an autocrine and endocrine hypothesis. Physiol Rev 1979;59:719-809.
13. Vague J. La différenciation sexuelle facteur déterminant des formes de l'obésité. Presse Med 1947;55:339-40.
14. Kiessebah AH, Krakower GR. Regional adiposity and morbidity. Physiol Rev 1994;74:775-811.
15. Kiessebah AH, Vydelingum N, Murray R, et al. Relation of body fat distribution to metabolic complications of obesity. J Clin Endocrin Metab 1982;54:254-60.
16. Yamashita S, Kazuaki K, Tadashi N, Yuzi M, Nishida M. Insulin resistance and body fat distribution. Diabetes Care 1996;19:346-50.
17. Matsuzawa Y, Shimomura I, Nakamura T, Keno Y, Takunaga K. Pathophysiology and pathogenesis of visceral fat obesity. Ann NY Acad Sci 1993;676:270-8.
18. Arner P. Not all fat is alike. Lancet 1998;351:1301-2.
19. Frayn KN. Physiological regulation of macronutrient balance. Int J Obes 1995;19:4-10
20. Polkow B. Stress: hypothalamic functions and neuroendocrine consequences. Acta Med Scand 1988;723:61-70.
21. Bjorntorp P. Metabolic implications of body fat distribution. Diabetes Care 1991;14:1132-43.
22. Amatruda JM, Livingstone JN, Lockwood DN. Cellular mechanism in selected states of insulin resistance: human obesity, glucocorticoid excess and chronic renal failure. Diabetes Metab Rev 1985;3:293-317.
23. Wilding J. Obesity treatment. BMJ. 1997;315:997-1000.
24. Qu D, Ludwig DS. A role for melanin concentrating hormone in the central regulation of feeding behaviour. Nature 1996;380:243-7.
25. Mounjoy KG, Wong J. Obesity, diabetes and functions for proopiomelanocortin-derived peptides. Mol Cell Endocrin 1997;128:171-7.
26. Matsunaga TO, Hruby VI. Melanin concentrating hormone (MCH) : Structure, function aspects of its melanocyte stimulating hormone like (MSH-like) activity. Peptides 1989;10: 773-8.
27. Miller CL, Hruby VI. α-MSH and MCH are functional antagonists in a central nervous system auditory gating paradigm. Ann NY Acad Sci 1993;680:571-4.
28. Curzon G, Gibson EL, Oluyomi AO. Appetite suppression by commonly used drugs depends on 5-HT availability. TIPS 1997;18:21-5.
29. Scheen AJ, Desaive C, Lefebvre PJ. Therapy for obesity -today and tomorrow. Clin Endocrinol Metab 1994;8:705-27.
30. Greenberg D. Is cholecystokinin the peptide that controls the food intake? Nutrition Review 1993;51:181-9.
31. Ballinger A, Mcloughlin L, Medbak S, Clark M. Cholecystokinin is a satiety hormone in humans at physiological postprandial plasma-concentrations. Clin Sci 1995;89:375-81.
32. Greenberg D, Torres NI, Smith GP, Gibbs J. The satiating effects of fats is attenuated by cholecystokinin antagonist-Lorglumide. Ann NY Acad Sci 1989;575:517-20.
33. Yox DP, Brenner L, Ritter RC. CCK- receptor antagonists attenuate suppression of sham feeding by intestinal nutrients. Am J Physiol 1992;262:554-61.
34. Gregory PC, McFadyn M, Duodenal infusion of fat, cholecystokinin secretion and satiety in the pig. Physiol Behav 1989;45:1021-4.
35. Reidelberger RD, Varga G, Solomon TE. Comparative effects of cholecystokinin (CCK-A) receptor antagonist L 364718 and CCK-B antagonist L365260 on solid food intake in rats. Soc Neurosci 1990;16:978.
36. Robin G. New approaches to the treatment of obesity. Pharmaceu J 1998;260:536-7.
37. Huszar D, Lynch CA, Dunmore JH, et al. Targeted disruption of melanocortin-4 receptors results in obesity in mice. Cell 1997;88:131-41.
38. Lu D, Willard D, Patel IR, Kadwell S, Overton L, Kost T. Agouti protein is an antagonist of the melanocyte stimulating hormone receptor. Nature 1994;371:799-802.
39. Hotamistigil GS, Peraldi P, Budavari A. IRS-1 mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α-and obesity induced insulin resistance. Science 1996; 27:665-8.
40. Hotamisligil GS, Murray DL, Choy LN. Tumour necrosis factor alpha inhibits signalling from the insulin receptor. Proc Natl Acad Sci 1994;91:4854-8.
41. Jeanrenaud B. CNS and peripheral abnormalities : clues to the understanding of obesity and NIDDM. Diabetologia 1994;37:170-8.
42. Hotamisligil GS, Arner P, Caro JF. Increased adipose tissue expression of tumor necrosis factor alpha in human obesity and insulin resistance. J Clin Invest 1995;95:2409-15.
43. Kern PA, Saghizad M, Ong JM. The expression of TNF factor in human adipose tissue: Regulation by obesity, weight loss and relationship to lipoprotein lipase. J Clin Invest 1995;95:2111-9.
44. Smith SR. The endocrinology of obesity. Endocrin Metab Clin North Am 1996;25:921-41.
45. Bergö M, Olivecrona G, Olivecrona T. Regulation of adipose tissue lipoprotein lipase in young and old rats. Int J Obes 1997;21:980-6.
46. Kern PA. Potential role of TNF - α- and lipoprotein lipase as candidate genes for obesity. J Nutr 1997; 127:1917-22.
47. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Freidman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994;372:425-32.
48. Auwerx J, Staels B. Leptin. Lancet 1998;351:737-42.
49. Sinha MK, Ohannesian JP, Heiman ML, et al. Nocturnal rise in leptin in lean, obese and NIDDM subjects. J Clin Invest 1996;97:1344-7.
50. Wang Q, Bing C, Al-Barazanji K, Mossakowaska DE, Wang X, McBay D. Interaction between leptin and hypothalamic neuropeptide Y neurons in the control of food intake and energy homeostasis in the rat. Diabetes 1997;46:335-41.
51. Montague CT, Farooqui IS, Whitehead JP, Soos MA, Rau H, Wareham NJ. Congenital leptin deficiency is associated with severe early - onset obesity in humans. Nature 1997;387:903-3.
52. Clement G. A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature 1998; 392:398-404.
53. Kausta E, Chrisoulidou A, Lawrence NJ, et al. The circadian rhythm of leptin is preserved in growth hormone deficient hypopituitary adults. Clin Endocrin 1998;48:685-90.
54. Spiegelman BM, Jeffrey SF. Adipogenesis and obesity: rounding out the big picture. Cell 1996;87:377-89.
55. Meier CA. Advances in the understanding of molecular basis of obesity. J Endocrin 1997;133:761-3.
56. 3-adrenergic receptor agonists in obese mice. Am J Physiol 1995:268:678-84.
57. Inui A. Feeding and body-weight regulation by hypothalamic neuropeptides-mediation of actions of leptin. TINS 1999;22:62-7.
58. 3-adrenergic receptor gene. J Biochem 1995;270:29483-92.
59. 3-adrenoceptor activities. J Biochem 1995;312:781-8.
60. 3-adrenergic receptor restores message and expression of brown fat mitochondrial uncoupling protein in adult dogs. Proc Natl Acad Sci 1991;88:10774-7.
61. 3-adrenergic receptor. Eur J Biochem 1994;224:761-70.
62. 3-adrenergic receptor gene. N Engl J Med 1995;333:343-7.
63. 3-adrenergic receptor and an increased capacity to gain weight in patients with morbid obesity. N Engl J Med 1995;333:352-4.
64. 3-adrenergic receptors. Ann Rev Pharmacol Toxicol 1997;37:421-50.
65. Nicholas DG, Locke RM. Thermogenic mechanisms in brown fat. Physiol Rev 1984;64:1-64.
66. Himms-Hagen J. Brown adipose tissue thermogenesis : interdisciplinary studies. FASEB J 1990;4:2890-8.
67. Garruti G, Ricquier D. Analysis of uncoupling proteins and its mRNA in adipose tissue deposits of adult humans. Int J Obes Relat Metab Disord 1992;16:283-390.
68. 3 adrenergic receptor Eur J Endocrin 1997;136: 362-5.
69. Fleury C, Neverrova M, Collins S, Raimbault S, Champigny O. Uncoupling protein-2: a novel gene linked to obesity and hyperinsulinaemia. Nat Genetics 1997;15:269-72.
70. VidalPuig A, Solanes G, Flier JS, Lowell BB. UCP-3 : an uncoupling protein homologue expressed preferentially and abundantly in skeletal muscle and brown adipose tissue. Biochem Biophys Res Commun 1997;235:79-82.
71. Macready N. The stubborn enigma of obesity. Lancet 1998; 351:888.
72. Foreyt JP, Poston CW. The role of the behavioural counsellor in obesity treatment. J Am Diet Assoc 1998;98:27-30.
73. Nonas CA. A model of chronic care of obesity through dietary treatment. J Am Diet Assoc 1998;98:16-22.
74. Silverstone T. Appetite suppressants-a review. Drugs 1992;43:820-36.
75. Bray GA. Use and abuse of appetite-suppressant drugs in the treatment of obesity. Ann Intern Med 1993;119:707-13.
76. Fricker J. Balancing the risks of antiobesity pills. The Lancet 1997;349-1374.
77. Connolly HM, Cray JL, McGoon MD. Valvular heart disease associated with fenfluramine-phentermine. N Eng J Med 1997;337:581-8.
78. Mathew T, Bradbury R, Desmond P, Lander C. Withdrawal of fenfluramine and dexfenfluramine. Australian Adverse Drug Reactions Bulletin 1998;17:1-4.
79. Ryan DH, Kaiser P, Bray GA. Sibutramine : a novel agent for obesity treatment. Obes Res 1995;3:553-9.
80. Rxan DH. Medicating the obese patient. Endocrin Metab Clin North Am 1996;25:989-1003.
81. Adult A. Newest anti-obesity drug fails to pass FDA muster. The Lancet 1998;351:885.
82. Astrup A, Breum L, Toubro S, Hein P, Quaade R. The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects. Int J Obes 1992;16:269-77.
83. Pasquali R, Casimirri F. Clinical aspects of ephedrine in the treatment of obesity. Int J Obes 1993;17:65-8
84. Greenway FL. Surgery for obesity. Metab Clin North Am 1996;25:1005-27.
85. Dietz WM, Goodwin NJ, Yanovski SZ. Long-term pharmcotherapy in the management of obesity. JAMA 1996;276:1907-15.
86. Inui A. Neuropeptide Y feeding receptors: are multiple subtypes involved? TIPS 1999;20:43-6.
87. Couceyro PR, Lambert PD. CART peptides : therapeutic potential in obesity and feeding disorders. Drug News Perspect 1999;12:133-6.
88. Harp JB. Orlistat for long term treatment of obesity. Drugs of Today 1999;35:139-45.